LanzaTech and TeselaGen Biotechnology signed a multi-year contract

Jennifer Holmgren, Ceo of LanzaTech

LanzaTech signed a new multi-year contract with TeselaGen Biotechnology, extending their relationship through 2025. The two companies have been collaborating since 2016 on the informatics behind high-throughput synthetic biology workflows. Over that time, LanzaTech has continued to experience rapid growth, shopping the feasibility to synthesize more than 100 different molecules using its carbon-eating bacteria, and demonstrating the need for a significant scaleup of its R&D operations.

Continue reading